1097 / 1816
Trial Design
Eligible patients
Breast only RT
40Gy in 15 #
(2.67Gy) 3 wks
N=1333
Annual clinical assessment
R
A
N
D
O
M
I
S
E
27Gy in 5 #
(5.4Gy) 5 days
N=1333
26Gy in 5 #
(5.2Gy) 5 days
N=1333
Recruitment
and consent
Radiotherapy
+/- boost
Primary endpoint:
- ipsilateral local tumour control
Secondary endpoints:
- early and late adverse effects in normal tissues,
- quality of life,
- contralateral primary tumours,
- regional and distant metastases
- survival.